Table 1.

Patient characteristics. Daclizumab (0.5 mg/kg) was administered 4 or 8 d before the first DC vaccination to deplete regulatory T cells. DTH – Delayed-type hypersensitivity reaction induced by injection of antigen-loaded dendritic cells. Skin-test infiltrating lymphocytes were analyzed for antigen-specificity and functionality ⁴⁰ – no specific T cells found, + tetramer-specific T cells, +++ functional, specific T cells. TT – Targeted therapy with BRAF inhibitor. I – Immunotherapy with anti-CTLA4 antibodies. RT – Radiotherapy. TMZ – Chemotherapy with Temozolomide.

							Tumor-specific CD8+ T cells
Patient	Age	Sex	Stage at baseline	AJCC stage	Sites of disease	Systemic pretreatment	Pre Blood	Post blood	Post DTH	Functional response blood4	PFS	OS	Response	Salvage treatment
I-B-04	31	f	M1c	IV	Liver	-		NA	+++	+	162+	162+	CR	None
I-C-04a	66	m	M1a	IV	LN	-		+	+++	+	13	43	SD	None
I-C-09	33	f	M1a	IV	LN	-		-	+++	+	139	180+	SD1	Surgery
II-E-08a	56	m	N3	IIIc	LN	-	+	+	+++	+	9	51	NED	DTIC
III-A-04a	28	f	M1c	IV	LN, retroperitoneal	Daclizumab 4		+	-	+	<4	13	PD	Unknown
III-A-06	68	f	M1c	IV	Lung, LN, skin	Daclizumab 4		-	+	-	5	25	PD	DTIC
III-A-07	25	m	M1c	IV	Liver, lung, LN, skin	Daclizumab 4		-	+	-	<4	7	PD	DTIC
III-B-01	53	f	M1b	IV	Lung, LN, skin	Daclizumab 8		-	+	-	<4	10	PD	DTIC
IV-A-01a	69	m	M1a	IV	LN, skin	DTIC		+	+++	+	39	128	MR	Surgery, I
IV-C-05a	31	f	M1c	IV	Lung, skin, breast	-	-	+	+	+	16	90+	SD2	Surgery
IV-C-12a	38	f	N1b	IIIb	LN	-	+	+	+++	+	8	16	NED	DTIC
IV-D-03a	42	f	M1c	IV	Liver, lung	DTIC	-	+	-	+	6	26	SD	TMZ
IV-D-06a	61	f	M1a	IV	LN	-	+	+	+++	+	15	24	SD	None
VI-B-01a	58	m	M1a	IV	Skin3	-	-	+	+++	+	18	22	SD	Surgery, TT
VI-B-03	48	f	M1a	IV	LN	-	-	-	-	-	7	40	SD	TT, I
VI-B-08	54	f	M1c	IV	Skin, muscle, intestine	-	+	+	+++	+	15	29	MR	I, RT, TT, Surgery
VI-B-10	66	f	M1c	IV	Lung, skin, mesentery	-	-	-	-	-	<4	32+	PD	TT, I
VI-B-11	48	m	M1c	IV	Lung, mesentery, intestine	-	+	+	-	-	<4	6	PD	None
VI-B-13	46	m	M1b	IV	LN, lung	-	-	+	+++	+	29+	29+	CR	None

^aSamples were stained with tetrameric MHC complexes.

¹Not evaluable for clinical response because no target lesion at start of vaccination

²Partial remission of a distant LN metastasis, CR after surgery for >10y

³The term ‘skin’ both includes subcutaneous and/or cutaneous metastasis.

⁴A functional response is determined positive when after background-subtraction more than 0.2% of CD8⁺ T cells express a functional marker.